Team Eagles, Owned by BLS International, Participates in the First World Tennis League

BLS International’s owned Team Eagles participates in The First World Tennis League

BLS International’s owned Team Eagles participates in The First World Tennis League

DUBAI, Arab Emirates, Dec. 23, 2022 (GLOBE NEWSWIRE) — Team Eagles, owned by BLS International Services Ltd., is participating in this season of the World Tennis League taking place from the 19th to the 24th of December 2022 in the Coca-Cola Arena, Dubai. World Tennis League is an exemplary blend of sports and entertainment, making for a unique experience, featuring world-renowned tennis players along with some preeminent artists from around the globe. The players’ lineup includes the legendary player Novak Djokovic, Iga Swiatek who has been currently ranked world No. 1 by the Women’s Tennis Association (WTA), Dominic Thiem who has been ranked as high as world No. 3 in singles by the Association of Tennis Professionals, and Anett Kontaveit who is the highest-ranked Estonian player in history, among several others. The league will follow a never seen format by dividing these players into four different teams: Eagles, Kites, Hawks, and Falcons. These matches will be followed by some compelling concerts by DJs and performers like Tiesto, NE-YO, WIZKID, Mohammad Ramadan, Deadmaus, and Armin Van Buuren.

Mr. Shikhar Aggarwal, the Joint Managing Director of BLS International, has been quoted saying, “BLS International is a trusted global, tech-enabled service provider for visa consular and digital services, and we rank amongst the top three players in the said domain. At BLS International, we have always believed in continuously expanding our horizons and developing a one-world network between different countries, cultures, and communities. With that vision, we embark on this exciting journey of becoming a part of the premier World Tennis League with our team, the Eagles! As we kick off this electrifying competition, to my team Nick, Rohan, Caroline, Bianca, and Andreas, I’d just like to say, may you all soar victoriously high, just like an eagle, as you keep your eye on the championship. To all the teams, here’s wishing you all the very best!”

About BLS International

BLS International Services Limited (“BLS International”), member of the exclusive club of Indian unicorns and a trusted global tech-enabled services partner for governments and citizens, has an impeccable reputation for setting benchmarks in the domain of visa, passport, consular, citizen, e-governance, attestation, biometric, e-visa, and retail services since 2005. The company is recognized as “India’s Most Valuable Companies” by Business Today Magazine, “Best under a Billion” company by Forbes Asia, and ranked amongst “Fortune India’s Next 500 companies”. BLS International has recently reached the market cap milestone of one billion dollars.

Contact Information:
Ekta Bhaskar
Global Head- Corporate Communications

Related Images

Image 1: BLS International’s owned Team Eagles participates in The First World Tennis League

The players’ lineup includes the legendary player Novak Djokovic, Iga Swiatek, Dominic Thiem, and Anett Kontaveit.

This content was issued through the press release distribution service at


GlobeNewswire Distribution ID 8719649

Myanmar’s casualties of war face a perilous journey

It was pitch black when Ku Phe Law stepped on a landmine and shattered his legs during a skirmish with Myanmar junta troops in eastern Kayah State earlier this year.


Drifting in and out of consciousness, the Karenni Nationalities Defence Force (KNDF) soldier was then taken on a grueling eight-hour car journey in a bid to save his life.


“It was quite far and it took a long time to reach. I don’t know what happened next,” said the 23-year-old, recalling how he ended up in a clinic close to the Thai border.


While his comrades in Loikaw in Kayah State didn’t have much in the way of medical resources, once he was in Thailand, he was outfitted with an artificial leg.


“I was there for 20 days in January, and took a break for a month in the camp. Then I had to go and stay for six months in (Kayah State),” Ku Phe Law added.


Even though his right leg was amputated below the knee, he was lucky to survive.


It has been nearly two years since the military seized power in Myanmar from the democratically elected government of now-imprisoned Aung San Suu Kyi. During that time, coup leader Senior Gen. Min Aung Hlaing has launched a brutal crackdown against the 8,000-strong KNDF, which has links to the pro-democracy alliance and is just one of the myriad forces battling the junta.


On the frontline, the fighting has been fierce, stretching medical resources to breaking point on the Myanmar side of the Thai border. Threadbare hospitals and medical supplies are inadequate for severely wounded soldiers. Crossing the border can at times be the only option.


Despite the perilous journey, many of the casualties of war have been referred to Mae Tao Clinic at Mae Sot in northwestern Thailand, which was established more than 30 years ago to provide free treatment for Burmese refugees and migrants. At least 148 victims of the war have been referred and treated there in the past 10 months, mostly men, but occasionally male and female villagers hit by shelling.


The number of landmine-related cases during that period was 17, the clinic says. In July there were 28 patients undergoing treatment – a monthly record.


“Mostly, they come here for treatment because it’s not easy to go to a local clinic, hospital, or military hospital [in Myanmar] for the sort of wounds they have,” said a medic from the Civil Disobedience Movement that emerged after the Feb. 1, 2021 coup, to oppose military rule. He asked for anonymity for safety reasons.


The Mae Tao Clinic is a well-established institution amid the often-fluid situation at the Thai-Myanmar border, and is supported by a wide range of donors who help pay for the treatment of patients.

The clinic works closely with local public health authorities in Thailand, and does not actually assist people with crossing the border.


“They travel through the dark or in the forest. Some people [have] paid a lot of money to get here. It is hugely difficult for people who do not have much money,” the medic said.


“Also, the border bridge is not open legally while the Thai army is watching [all the time]. To come here is very hard,” he said. “Even if they can enter Thailand, they don’t know how to speak [Thai] and are afraid of the police.”


At the height of the Civil Disobedience Movement, doctors and medical students were among the most vocal opponents of the Myanmar military regime. They are still targeted by the junta and many have either left Myanmar or moved to parts of the country controlled by pro-democracy forces.


The conflict, which shows no sign of easing, has exacted a heavy toll. The Thailand-based Assistance Association for Political Prisoners (Burma) has recorded the killings by junta forces of more than 2,600 civilians since the coup. Some 1.1 million others have been displaced. The true death toll could be much higher.


Hospital facilities inside Myanmar can be basic and there is a scarcity of medical supplies, amid continued fighting between the Myanmar army and ethnic armed organizations on the border, and People’s Defense Forces across the country.


“For ordinary injuries, they’re treated in the temporary camps in the forest away from the battlefield, but for the emergency cases [that is different]. They are sent to the hospitals on the Thai border and treated,” said one doctor, who fled to Kayin State from the city of Mawlamyine and asked not to be identified because of fear of reprisals.


“But for our injured comrades who need treatment in Thailand, they have no choice – even though staying in the country is illegal,” the doctor added.


As for KNDF soldier Ku Phe Law, who now works on the administrative side of the ethnic armed organization, his loyalty to the pro-democracy movement remains strong, despite his brush with death.


“I don’t like the dictatorship and what the junta does,” he said. “I have seen many innocent civilians injured and killed – and that shouldn’t happen.”


Radio Free Asia Copyright © 1998-2016, RFA. Used with the permission of Radio Free Asia, 2025 M St. NW, Suite 300, Washington DC 20036

Notorious French Serial Killer Freed from Nepal Prison

KATHMANDU, NEPAL — Confessed French serial killer Charles Sobhraj was freed from prison in Nepal on Friday after serving most of his sentence for the murders of American and Canadian backpackers.


Sobhraj was driven out of Central Jail in Kathmandu in a heavily guarded police convoy to the Department of Immigration, where he will wait for his travel documents to be prepared.


The country’s Supreme Court had ordered that Sobhraj, who was sentenced to life in prison in Nepal, be released because of poor health, good behavior and having already served most of his sentence. Life sentences in Nepal are 20 years.


The order also said he had to leave the country within 15 days.


Sobhraj’s attorney Gopal Siwakoti Chitan told reporters that the request for the travel documents must be made by the immigration department to the French embassy in Nepal, which could take some time. Offices are closed over the weekend for the Christmas holiday.


The court document said he had already served more than 75% of his sentence, making him eligible for release, and he has heart disease.


The Frenchman has in the past admitted killing several Western tourists and he is believed to have killed at least 20 people in Afghanistan, India, Thailand, Turkey, Nepal, Iran and Hong Kong during the 1970s. However, his 2004 conviction in Nepal was the first time he was found guilty in court.


Sobhraj was held for two decades in New Delhi’s maximum-security Tihar prison on suspicion of theft but was deported without charge to France in 1997. He resurfaced in September 2003 in Kathmandu.


His nickname, The Serpent, stems from his reputation as a disguise and escape artist.


Source: Voice of America

UNHCR urges States to act now to save lives in the Andaman Sea

UNHCR, the UN Refugee Agency, is reminding States in the region that some 190 desperate people are on the verge of perishing at sea, adrift somewhere between the Andaman Sea and the Bay of Bengal as pleas to rescue and disembark them are continuously ignored.


Reports indicate those onboard have now remained at sea for a month in dire conditions with insufficient food or water, without any efforts by States in the region to help save human lives. Many are women and children, with reports of up to 20 people dying on the unseaworthy vessel during the journey.


“This shocking ordeal and tragedy must not continue. These are human beings – men, women and children. We need to see the States in the region help save lives and not let people die,’’ said Indrika Ratwatte, UNHCR’s Director for Asia and the Pacific.


Since the first reports of the boat being sighted in Thai waters, UNHCR has received unverified information of the vessel being spotted near Indonesia and then subsequently off the coast of the Andaman and Nicobar Islands of India. The boat’s current location is reportedly once more back eastwards, in the Andaman sea north of Aceh.


UNHCR has repeatedly asked all countries in the region to make saving lives a priority. The agency had alerted the Indian marine rescue centre earlier this week, requesting immediate action to save lives and allow for disembarkations.


“It is devastating to learn that many people have already lost their lives, including children,’’ added UNHCR’s Ratwatte. “Sadly, this makes it one of the deadliest years in the seas in the region.’’


It is very hard for UNHCR to verify this information, but if true this will take the number of dead and missing in the Bay of Bengal and the Andaman Sea to nearly 200 this year. A shocking number that represents around 10 per cent of the estimated 2,000 people who have taken risky sea journeys in the region in 2022.


All States have a responsibility to rescue those on the boat and allow them to safely disembark in line with legal obligations and in the name of humanity.


Source: UN High Commissioner for Refugees

PM announces his decision to join United Thai Nation Party

Prime Minister Prayut Chan-o-cha announced today (Friday) that he has decided to join the United Thai Nation Party (Ruam Thai Sang Chart), ending months-long speculation about when he will formally join which party to contest the next election.


He told the media at Government House that he decided to join the United Thai Nation Party after it undertook to nominate him as the party’s candidate for the premiership post, adding that he will now apply for party membership.


He said that he had been preparing for some time to join the party, hoping that all parties concerned will be relieved by his decision today. He also said that it will depend on the people as to whether they will support him.


Explaining his decision today, the prime minister said that there are still several unfinished projects, which were initiated by his government over the past four years, which he would like to continue to completion.


He said that he has already informed Deputy Prime Minister Prawit Wongsuwan, leader of the ruling Palang Pracharath Party, about his decision to join the United Thai Nation Party, adding that there is no conflict between them, as he insisted that his decision is in line with the democratic system.


He also insisted that his relationship with General Prawit remains unchanged, as both of them are still on speaking terms. “He was my first superior after graduation from the Chulachomklao Royal Military Academy. We have been together all along.  Our bond is unbreakable,” said the prime minister.


The prime minister’s political decision today is expected to lead to the defection of several MPs from the Palang Pracharath Party, particularly a faction led by Labour Minister Suchart Chomklin.


The United Thai Nation Party is led by Pirapan Salirathavibhaga, former Democrat MP and now secretary-general of the Prime Minister’s Office.


Source: Thai Public Broadcasting Service

Thailand launches third phase of GPO’s inactivated COVID vaccine trials

Thailand’s Government Pharmaceutical Organisation (GPO) launched the third phase of human trials of its COVID HXP-GPOVac on 4,000 volunteers today (Friday), after the success of the second phase involving 300 volunteers.


Each volunteer will be given two doses of vaccine, of 10 micrograms each at least 14 days apart, after which their blood will be taken for tests, to check the level of immunity. Doctors will also assess the safety of the vaccine in humans and compare its efficacy against that of the AstraZeneca vaccine, which is also an inactivated vaccine. The vaccine will be used as booster.


Volunteers must be at least 18-years-old, physically healthy, without underlying diseases and not infected with COVID-19 in the past three months.


If the results of the third phase are satisfactory, the GPO will apply to register the HXP-GPOVac with the Thai Food and Drug Administration, to be used in cases of emergency, tentatively, in the middle of next year.

Public Health Minister Anutin Charnvirakul said today that the GPO’s vaccine is quite safe because it is an inactivated vaccine, and that he hopes that the vaccine will enhance Thailand’s vaccine security and help reduce dependence on imported vaccines.


He also expressed his appreciation to all the volunteers for their sacrifice by taking part in the human trial.


Launched in May 2020, the GPO’s vaccine development project is supported by PATH, a global non-profit health organisation, which has provided the GPO with a prototype, jointly developed by the Icahn School of Medicine at Mount Sinai and the University of Texas in Austin in the United States.


The prototype vaccine has been used in the research, development and production of the HXP-GPOVac candidate,which is an inactivated chimeric vaccine.


The Faculty of Medicine at Chulalongkorn University is also researching an mRNA COVID vaccine, whereas Baiya Phytopharm Company, a start-up of the Faculty of Pharmacy at Chulalongkorn University, is also engaged in the second phase development of its plant-based COVID vaccine.


Source: Thai Public Broadcasting Service

Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program


Nyxoah Files Shelf Registration Statement and
Announces At-the-Market Equity Offering Program

Mont-Saint-Guibert, Belgium – December 22, 2022, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has filed a $200 million shelf registration statement on Form F-3 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”).  Once declared effective by the SEC, the Registration Statement would permit the Company to sell, from time to time, up to $200 million in aggregate value of its common stock, preferred stock, debt securities, warrants, and/or units. The Registration Statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.

The Company also entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), as sales agent, pursuant to which the Company may sell new ordinary shares having an aggregate offering price of up to $50 million (the “Offered Shares”) from time to time through an “at-the-market” offering (the “ATM”). The actual number of Offered Shares to be issued, if any, will depend on the Company’s determination, in its sole discretion, to make sales and the price per share of any such sales. However, the number of Offered Shares shall not exceed 6 million shares. The Offered Shares will be sold at a sales price per Offered Share equal to the then current USD market price of the Nyxoah ordinary share on the Nasdaq Global Market at the time of the relevant sale.

Cantor may sell Offered Shares by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made directly on the Nasdaq Stock Market, on any other existing U.S. trading market for the ordinary shares, or to or through a market maker.  Since the Offered Shares will be sold at market prices prevailing at the time of the sale, sales prices may vary.  No sales of Offered Shares will be conducted in Belgium or through Euronext.

The ATM offering is being made only by means of a prospectus included within the Registration Statement.  The Registration Statement has not yet become effective.  These securities may not be sold nor may offers to buy these securities be accepted prior to the time the Registration Statement becomes effective.  When available, copies of the prospectus relating to the ATM may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, New York, NY 10022, or by email:

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s current expectations regarding the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Loic Moreau, Chief Financial Officer
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
+1 917 749 1494


GlobeNewswire Distribution ID 1000773914

Synchronoss ประกาศจำนวนผู้สมัครใช้บริการส่งข้อความบน RCS กว่า 30 ล้านคนในญี่ปุ่น

การใช้งานแพลตฟอร์ม Synchronoss Advanced Messaging ช่วยให้ NTT DOCOMO, KDDI และ SoftBank สามารถมอบบริการการส่งข้อความขั้นสูงระหว่างผู้ให้บริการโทรศัพท์ ซึ่งช่วยผู้ใช้และแบรนด์ต่าง ๆ สามารถสื่อสาร โต้ตอบ และทำธุรกรรมได้

BRIDGEWATER, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” หรือ “บริษัท”) (NASDAQ: SNCR) ผู้นำระดับโลกและผู้ริเริ่มผลิตภัณฑ์และแพลตฟอร์มระบบคลาวด์ การส่งข้อความ และระบบดิจิทัล ประกาศความสำเร็จครั้งใหม่ในญี่ปุ่นสำหรับแพลตฟอร์ม Synchronoss Advanced Messaging ด้วยความร่วมมือกับผู้ให้บริการโทรศัพท์มือถืออย่าง NTT DOCOMO, KDDI และ SoftBank กลุ่มบริษัทร่วมทุนสัญชาติญี่ปุ่นนี้รองรับการใช้งานสำหรับสมาชิก +Message ซึ่งเป็นบริการ RCS ระหว่างผู้ให้บริการที่ขับเคลื่อนโดย Synchronoss Advanced Messaging กว่า 32.5 ล้านรายในปัจจุบัน

เหตุการณ์สำคัญในปัจจุบันนี้แสดงให้เห็นถึงจำนวนสมาชิกที่เพิ่มขึ้นถึงร้อยละ 62 เนื่องจาก Synchronoss สังเกตเห็นความคืบหน้าของการปรับใช้มาตรฐานอุตสาหกรรมสำหรับการรับส่งข้อความ (RCS) ของกลุ่มบริษัทร่วมทุนญี่ปุ่นในเดือนพฤศจิกายน 2563

+Messaging นำเสนอระบบส่งข้อความที่มีคุณสมบัติหลากหลาย ซึ่งช่วยให้ผู้ใช้ภาษาญี่ปุ่นสามารถสื่อสารกับเพื่อน ๆ และครอบครัวได้ นอกจากนี้ยังมาพร้อมความสามารถในการโต้ตอบและมีส่วนร่วมกับแบรนด์และธุรกิจได้อย่างปลอดภัยและรัดกุม

บริการ +Messaging ของกลุ่มบริษัทร่วมทุนนี้ขับเคลื่อนโดย Synchronoss Advanced Messaging ซึ่งเป็นแพลตฟอร์มครบวงจรและผลิตภัณฑ์สำหรับโทรศัพท์มือถือที่ช่วยให้ผู้ให้บริการสามารถส่งมอบระบบนิเวศการส่งข้อความขั้นสูงได้ Synchronoss Advanced Messaging เชื่อมต่อแบรนด์และผู้ให้บริการเนื้อหากับสมาชิก โดยนำเสนอวิธีการใหม่ ๆ ในการสื่อสารและทำธุรกรรมเชิงพาณิชย์

Yosuke Morioka ผู้จัดการทั่วไปประจำประเทศญี่ปุ่นของ Synchronoss กล่าวว่า “บริการ +Messaging ที่ได้รับการยอมรับจากสมาชิกกว่า 30 ล้านรายในญี่ปุ่นเป็นเครื่องช่วยยืนยันถึงคุณค่าของ RCS และวิธีที่ผู้ให้บริการโทรศัพท์มือถือสามารถใช้ประโยชน์จาก RCS เพื่อนำเสนอบริการใหม่ ๆ ที่สร้างรายได้” “เราคาดหวังว่าจะได้ร่วมงานกับ NTT DOCOMO, KDDI และ SoftBank ในเร็ว ๆ นี้เพื่อสำรวจโอกาสทางการตลาดเพิ่มเติมสำหรับแพลตฟอร์มเทคโนโลยีที่เพียบพร้อมด้วยคุณสมบัตินี้”

ปัจจุบัน +Message มีให้บริการบนโทรศัพท์มือถือทุกแบรนด์ของผู้ให้บริการทั้ง 3 รายและ MVNO นอกจากนี้ยังรองรับการระบุตัวตนสาธารณะ (JPKI) ด้วยบัตร My Number ซึ่งช่วยให้ผู้ใช้สามารถเปิดบัญชีธนาคารหรือใช้บัตรเครดิตด้วยการยืนยันตัวตนที่ง่ายและปลอดภัยผ่าน +Message มอบประสบการณ์ที่น่าดึงดูดใจยิ่งขึ้นภายในระบบนิเวศบนโทรศัพท์มือถือ

เกี่ยวกับ Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) สร้างซอฟต์แวร์ที่ช่วยให้บริษัทต่าง ๆ ทั่วโลกเชื่อมต่อกับสมาชิกด้วยวิธีที่น่าเชื่อถือและเต็มเปี่ยมไปด้วยความหมาย กลุ่มผลิตภัณฑ์ของบริษัทช่วยให้เครือข่ายมีความคล่องตัว ลดความซับซ้อนของการเริ่มใช้งาน และดึงดูดสมาชิกเพื่อสร้างเสริมแหล่งรายได้ใหม่ ลดต้นทุน และเพิ่มความเร็วสู่ตลาด สมาชิกหลายร้อยล้านคนไว้วางใจให้ผลิตภัณฑ์ Synchronoss เชื่อมต่อกับผู้คน บริการ และเนื้อหาที่ตนชื่นชอบ เรียนรู้เพิ่มเติมได้ที่

Domenick Cilea

Matt Glover / Tom Colton
Gateway Group, Inc.

GlobeNewswire Distribution ID 8719420